Delivery Order SPE2DB20D1100-SPE2DB25FD6V8
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,007.80 for NovoLog 100 Unit/ML FlexPen 3ML insulin pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,751.48 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to supply pharmaceutical products supporting federal military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,150.32. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $4,406.16 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,167.15 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply agreements with the agency. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a $8,495.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of July 21, 2025. This non-set-aside contract was competitively awarded on July 18, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal healthcare needs, specifically for diabetes...
- The Defense Logistics Agency awarded a delivery order valued at $20,440.89 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to supply insulin medication to support federal healthcare needs. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $9,353.44 firm fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on July 21, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The delivery order, which represents a non-competitive set-aside award, is scheduled for completion by July 22, 2025, with performance occurring at the vendor's Conshohocken facility. This delivery order is issued...
- The Defense Logistics Agency awarded a $2,289.71 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,405.80 and an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively as a child contract under AmerisourceBergen's larger DLA prime vendor contract vehicle. The place of performance is listed as...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD6V8Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,392.51 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value pharmaceutical procurement to support federal medical supply requirements. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a wide range of pharmaceutical products and medical supplies to support military and veteran healthcare systems through the Defense Health Agency and related government healthcare entities. The parent IDC demonstrates the company's capability to fulfill diverse medical supply needs across multiple therapeutic domains through open competition and firm fixed pricing mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.4k | 7/28/25 |